Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy

BACKGROUND: High risk of recurrence/progression bladder tumours is treated with Bacillus Calmette-Guérin (BCG) immunotherapy after complete resection of the tumour. Approximately 75% of these tumours express the uncommon carbohydrate antigen sialyl-Tn (Tn), a surrogate biomarker of tumour aggressive...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, L, Severino, P F, Silva, M, Miranda, A, Tavares, A, Pereira, S, Fernandes, E, Cruz, R, Amaro, T, Reis, C A, Dall'Olio, F, Amado, F, Videira, P A, Santos, L, Ferreira, J A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798967/
https://www.ncbi.nlm.nih.gov/pubmed/24064971
http://dx.doi.org/10.1038/bjc.2013.571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798967/
https://www.ncbi.nlm.nih.gov/pubmed/24064971
http://dx.doi.org/10.1038/bjc.2013.571

Ejemplares similares